Stock Analysis
Redx Pharma (LON:REDX) Full Year 2023 Results
Key Financial Results
- Revenue: UK£4.20m (down 78% from FY 2022).
- Net loss: UK£33.2m (loss widened by 84% from FY 2022).
- UK£0.099 loss per share (further deteriorated from UK£0.061 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Redx Pharma Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 40%. Earnings per share (EPS) also surpassed analyst estimates by 17%.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Redx Pharma (including 1 which is a bit unpleasant).
Valuation is complex, but we're helping make it simple.
Find out whether Redx Pharma is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:REDX
Redx Pharma
Engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom.
